Home

Parti peggio costantemente e7107 clinical trial Standard media miscuglio

SF3B1 homeostasis is critical for survival and therapeutic response in T  cell leukemia
SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia

Microbial and Natural Metabolites That Inhibit Splicing: A Powerful  Alternative for Cancer Treatment
Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment

Frontiers | Innovative Therapeutic and Delivery Approaches Using  Nanotechnology to Correct Splicing Defects Underlying Disease | Genetics
Frontiers | Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease | Genetics

RCSB PDB - 5ZYA: SF3b spliceosomal complex bound to E7107
RCSB PDB - 5ZYA: SF3b spliceosomal complex bound to E7107

A phase I, open-label, single-arm, dose-escalation study of E7107, a  precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor  administered intravenously on days 1 and 8 every 21 days to patients with  solid tumors
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Splicing modulators: on the way from nature to clinic | The Journal of  Antibiotics
Splicing modulators: on the way from nature to clinic | The Journal of Antibiotics

Cancers | Free Full-Text | Somatic Mutations in Core Spliceosome Components  Promote Tumorigenesis and Generate an Exploitable Vulnerability in Human  Cancer | HTML
Cancers | Free Full-Text | Somatic Mutations in Core Spliceosome Components Promote Tumorigenesis and Generate an Exploitable Vulnerability in Human Cancer | HTML

Scalable Synthesis of 17S-FD-895 Expands the Structural Understanding of  Splice Modulatory Activity - ScienceDirect
Scalable Synthesis of 17S-FD-895 Expands the Structural Understanding of Splice Modulatory Activity - ScienceDirect

E7107
E7107

The catalytic spliceosome inhibitor E7107 induces IR and has potent... |  Download Scientific Diagram
The catalytic spliceosome inhibitor E7107 induces IR and has potent... | Download Scientific Diagram

A phase I, open-label, single-arm, dose-escalation study of E7107, a  precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor  administered intravenously on days 1 and 8 every 21 days to patients with  solid tumors
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Splicing modulation as novel therapeutic strategy against diffuse malignant  peritoneal mesothelioma - ScienceDirect
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma - ScienceDirect

The catalytic spliceosome inhibitor E7107 induces IR and has potent... |  Download Scientific Diagram
The catalytic spliceosome inhibitor E7107 induces IR and has potent... | Download Scientific Diagram

Roles and mechanisms of alternative splicing in cancer — implications for  care | Nature Reviews Clinical Oncology
Roles and mechanisms of alternative splicing in cancer — implications for care | Nature Reviews Clinical Oncology

Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant  Disease: Trends in Molecular Medicine
Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease: Trends in Molecular Medicine

Proteasome inhibitor-induced modulation reveals the spliceosome as a  specific therapeutic vulnerability in multiple myeloma | bioRxiv
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma | bioRxiv

RCSB PDB - 5ZYA: SF3b spliceosomal complex bound to E7107
RCSB PDB - 5ZYA: SF3b spliceosomal complex bound to E7107

Preclinical Evaluation and Development of New Therapeutic Strategies in  Myeloma | Wiita Lab at UCSF
Preclinical Evaluation and Development of New Therapeutic Strategies in Myeloma | Wiita Lab at UCSF

IJMS | Free Full-Text | Therapeutic Targeting of Alternative RNA Splicing  in Gastrointestinal Malignancies and Other Cancers | HTML
IJMS | Free Full-Text | Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers | HTML

A Comprehensive Overview of Structure‐Activity Relationships of  Small‐Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents -  Zhang - 2020 - ChemMedChem - Wiley Online Library
A Comprehensive Overview of Structure‐Activity Relationships of Small‐Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents - Zhang - 2020 - ChemMedChem - Wiley Online Library

E7107 induced tumor regression and extended survival in an orthotopic... |  Download Scientific Diagram
E7107 induced tumor regression and extended survival in an orthotopic... | Download Scientific Diagram

The synthesis and evaluation of the antiproliferative activity of  deacidified GEX1A analogues | The Journal of Antibiotics
The synthesis and evaluation of the antiproliferative activity of deacidified GEX1A analogues | The Journal of Antibiotics

Dysregulated Alternative Splicing Landscape Identifies Intron Retention as  a Hallmark and Spliceosome as a Therapeutic Vulnerability in Aggressive  Prostate Cancer | bioRxiv
Dysregulated Alternative Splicing Landscape Identifies Intron Retention as a Hallmark and Spliceosome as a Therapeutic Vulnerability in Aggressive Prostate Cancer | bioRxiv

SF3B1 modulators affect key genes in metastasis and drug influx: a new  approach to fight pancreatic cancer chemoresistance
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

E7107 | CAS#630100-90-2 | spliceosome inhibitor | MedKoo
E7107 | CAS#630100-90-2 | spliceosome inhibitor | MedKoo